-
Something wrong with this record ?
Feasibility of atlas-based active bone marrow sparing intensity modulated radiation therapy for cervical cancer
N. Li, SS. Noticewala, CW. Williamson, H. Shen, I. Sirak, R. Tarnawski, U. Mahantshetty, CK. Hoh, KL. Moore, LK. Mell,
Language English Country Ireland
Document type Journal Article
- MeSH
- Radiotherapy Dosage MeSH
- Adult MeSH
- Fluorodeoxyglucose F18 MeSH
- Bone Marrow radiation effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Uterine Cervical Neoplasms radiotherapy MeSH
- Positron Emission Tomography Computed Tomography MeSH
- Radiotherapy Planning, Computer-Assisted methods MeSH
- Radiotherapy, Intensity-Modulated adverse effects methods MeSH
- Aged MeSH
- Feasibility Studies MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: To test the hypothesis that atlas-based active bone marrow (ABM)-sparing intensity modulated radiation therapy (IMRT) yields similar dosimetric results compared to custom ABM-sparing IMRT for cervical cancer patients. METHODS: We sampled 62 cervical cancer patients with pre-treatment FDG-PET/CT in training (n=32) or test (n=30) sets. ABM was defined as the subvolume of the pelvic bone marrow (PBM) with standardized uptake value (SUV) above the mean on the average FDG-PET image (ABMAtlas) vs. the individual's PET (ABMCustom). Both were deformed to the planning CT. Overlap between the two subvolumes was measured using the Dice coefficient. Three IMRT plans designed to spare PBM, ABMAtlas, or ABMCustomwere compared for 30 test patients. Dosimetric parameters were used to evaluate plan quality. RESULTS: ABMAtlasand ABMCustomvolumes were not significantly different (p=0.90), with a mean Dice coefficient of 0.75, indicating good agreement. Compared to IMRT plans designed to spare PBM and ABMCustom, ABMAtlas-sparing IMRT plans achieved excellent target coverage and normal tissue sparing, without reducing dose to ABMCustom(mean ABMCustomdose 29.4Gy vs. 27.1Gyvs. 26.9Gy, respectively; p=0.10); however, PTV coverage and bowel sparing were slightly reduced. CONCLUSIONS: Atlas-based ABM sparing IMRT is clinically feasible and may obviate the need for customized ABM-sparing as a strategy to reduce hematologic toxicity.
Department of Oncology and Radiotherapy University Hospital Hradec Kralove Czech Republic
Department of Radiation Oncology Tata Memorial Hospital Mumbai India
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18010544
- 003
- CZ-PrNML
- 005
- 20180426085651.0
- 007
- ta
- 008
- 180404s2017 ie f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.radonc.2017.02.017 $2 doi
- 035 __
- $a (PubMed)28528206
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Li, Nan $u Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, United States.
- 245 10
- $a Feasibility of atlas-based active bone marrow sparing intensity modulated radiation therapy for cervical cancer / $c N. Li, SS. Noticewala, CW. Williamson, H. Shen, I. Sirak, R. Tarnawski, U. Mahantshetty, CK. Hoh, KL. Moore, LK. Mell,
- 520 9_
- $a BACKGROUND: To test the hypothesis that atlas-based active bone marrow (ABM)-sparing intensity modulated radiation therapy (IMRT) yields similar dosimetric results compared to custom ABM-sparing IMRT for cervical cancer patients. METHODS: We sampled 62 cervical cancer patients with pre-treatment FDG-PET/CT in training (n=32) or test (n=30) sets. ABM was defined as the subvolume of the pelvic bone marrow (PBM) with standardized uptake value (SUV) above the mean on the average FDG-PET image (ABMAtlas) vs. the individual's PET (ABMCustom). Both were deformed to the planning CT. Overlap between the two subvolumes was measured using the Dice coefficient. Three IMRT plans designed to spare PBM, ABMAtlas, or ABMCustomwere compared for 30 test patients. Dosimetric parameters were used to evaluate plan quality. RESULTS: ABMAtlasand ABMCustomvolumes were not significantly different (p=0.90), with a mean Dice coefficient of 0.75, indicating good agreement. Compared to IMRT plans designed to spare PBM and ABMCustom, ABMAtlas-sparing IMRT plans achieved excellent target coverage and normal tissue sparing, without reducing dose to ABMCustom(mean ABMCustomdose 29.4Gy vs. 27.1Gyvs. 26.9Gy, respectively; p=0.10); however, PTV coverage and bowel sparing were slightly reduced. CONCLUSIONS: Atlas-based ABM sparing IMRT is clinically feasible and may obviate the need for customized ABM-sparing as a strategy to reduce hematologic toxicity.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a kostní dřeň $x účinky záření $7 D001853
- 650 _2
- $a studie proveditelnosti $7 D005240
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fluorodeoxyglukosa F18 $7 D019788
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a PET/CT $7 D000072078
- 650 _2
- $a celková dávka radioterapie $7 D011879
- 650 _2
- $a plánování radioterapie pomocí počítače $x metody $7 D011880
- 650 _2
- $a radioterapie s modulovanou intenzitou $x škodlivé účinky $x metody $7 D050397
- 650 _2
- $a nádory děložního čípku $x radioterapie $7 D002583
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Noticewala, Sonal S $u Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, United States.
- 700 1_
- $a Williamson, Casey W $u Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, United States.
- 700 1_
- $a Shen, Hanjie $u Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, United States.
- 700 1_
- $a Sirak, Igor $u Department of Oncology and Radiotherapy, University Hospital, Hradec Kralove, Czech Republic.
- 700 1_
- $a Tarnawski, Rafal $u Clinic of Radiotherapy, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland.
- 700 1_
- $a Mahantshetty, Umesh $u Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India.
- 700 1_
- $a Hoh, Carl K $u Department of Radiology, Division of Nuclear Medicine, University of California San Diego, La Jolla, United States.
- 700 1_
- $a Moore, Kevin L $u Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, United States.
- 700 1_
- $a Mell, Loren K $u Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, United States. Electronic address: lmell@ucsd.edu.
- 773 0_
- $w MED00004049 $t Radiotherapy and oncology journal of the European Society for Therapeutic Radiology and Oncology $x 1879-0887 $g Roč. 123, č. 2 (2017), s. 325-330
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28528206 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20180426085801 $b ABA008
- 999 __
- $a ok $b bmc $g 1288029 $s 1007356
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 123 $c 2 $d 325-330 $i 1879-0887 $m Radiotherapy and oncology $n Radiother Oncol $x MED00004049
- LZP __
- $a Pubmed-20180404
